NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- 21Shares US LLC today announced the renaming of the 21Shares Ethereum Core ETF (CETH) or “the Fund” to the 21Shares Ethereum ETF (TETH), effective August 28, 2025. The changes do not affect investment objectives, principal investment strategies or any other aspect of operations. Client holdings remain unaffected by the change. Along with the renaming of the Fund, the ticker has changed from CETH to TETH. The Fund will continue to track the performance of ether, th ...

Nuvini CEO Pierre Schurmann to Host Investor Webinar on Tuesday, September 30, 2025 at 10:00a.m. Eastern TimeNEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading technology conglomerate in the Latin American SaaS sector, today announced that it will release its financial results for the first half of 2025 on Tuesday, September 30, 2025 before market open. The Company will also be hosting an Investor Webinar on Tuesday, September 30 at 10:00 a ...

The project will evaluate the integration of Eye-Net’s advanced safety technology into Continental’s vehicle platforms Ness Ziona, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced that its wholly-owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net”), has signed an agreement for a proof of concept (POC) project with co-pace GmbH (“co-pace”), the startup-up subsidiary of the technol ...

Core Insights - Firefly Neuroscience has launched its new 'CLEAR' Platform, which enhances EEG data quality and processing speed, utilizing NVIDIA's L40S GPU technology [1][3] - The CLEAR Platform significantly improves the reliability of EEG recordings by reducing noise and artifacts, enabling better detection of neural biomarkers for neurological and psychiatric conditions [2][4] - The platform achieves a 60-80% improvement in processing times, leveraging advanced signal processing and machine learning techniques [3][4] Company Overview - Firefly Neuroscience is focused on developing AI-driven solutions to improve brain health outcomes for patients with neurological and mental disorders [5][6] - The company has built a comprehensive database of brain wave tests over the past 15 years, securing patent protection and achieving FDA clearance for its Brain Network Analytics (BNA™) technology [5][6] - BNA™ technology aims to enhance diagnostic and treatment monitoring methods for various conditions, including depression, dementia, and ADHD [5][6]

Company Overview - Dynamix Corporation is a publicly-traded special purpose acquisition company (SPAC) incorporated in the Cayman Islands, focused on mergers and business combinations [6] - The company is led by experienced executives including CEO Andrejka Bernatova and CFO Nader Daylami [6] Business Combination - Dynamix Corporation announced a business combination with The Ether Reserve, LLC to form The Ether Machine, a strategic ether generation company [2][4] - The Ether Machine aims to deliver long-term, risk-adjusted yield through staking, restaking, and decentralized finance, with a focus on growing ether concentration per share [2][5] Ticker Symbol Change - The ticker symbols for Dynamix's common stock, units, and warrants will change from "DYNX," "DYNXU," and "DYNXW" to "ETHM," "ETHMU," and "ETHMW," respectively, effective August 27, 2025 [1][4] - This change is intended to facilitate a smooth transition for shareholders ahead of the business combination [3] Strategic Goals - The Ether Machine is expected to have one of the largest on-chain ETH positions of any public entity and will focus on generating and optimizing ETH-denominated returns [5] - The company plans to provide turnkey infrastructure solutions for enterprises and Ethereum-native builders [5] Approval and Timeline - The business combination has been unanimously approved by the boards of directors of both companies and is expected to close by the fourth quarter of 2025, pending shareholder approval [4]

Core Points - Plus Therapeutics, Inc. has confirmed compliance with Nasdaq Listing Rule 5550(b), meeting both the Market Value of Listing Securities (MVLS) standard of at least $35 million and the stockholders' equity threshold of at least $2.5 million [1][2] - Nasdaq has granted Plus Therapeutics an extension until November 12, 2025, to regain compliance with the $1.00 bid price rule, previously set for September 8, 2025 [2] - The company is under a one-year monitoring period for the Equity Standard, which will last until August 22, 2026, during which it must maintain compliance to avoid delisting [3] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for central nervous system cancers [4] - The company employs advanced technologies combining image-guided local beta radiation and targeted drug delivery, with key programs targeting leptomeningeal metastases and recurrent glioblastoma [4] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

Core Viewpoint - Orchestra BioMed Holdings, Inc. announced favorable hemodynamic effects of AVIM therapy for patients with uncontrolled hypertension, as published in the Journal of the American College of Cardiology: Clinical Electrophysiology [1][2][3] Group 1: AVIM Therapy Findings - AVIM therapy demonstrated statistically significant reductions in systolic blood pressure (SBP) by an average of 17.1 mmHg (RV pacing) and 19.2 mmHg (CSP), compared to 1.7 mmHg with standard pacing [6] - The therapy improved left ventricular hemodynamics, with end-diastolic volume decreasing by 12.6 mL (RV) and 18.6 mL (CSP), and end-systolic volume decreasing by 11.0 mL (RV) and 14.1 mL (CSP) [6] - AVIM therapy also significantly reduced cardiac workload, with stroke work decreasing by 1,596 mL (RV) and 1,870 mL (CSP), compared to 42 mL with standard pacing [6] Group 2: Clinical Implications - The publication of the data in a peer-reviewed journal reinforces the therapeutic rationale behind AVIM therapy, highlighting its potential to deliver differentiated clinical benefits for patients with uncontrolled hypertension [3][7] - AVIM therapy has received FDA Breakthrough Device Designation for treating uncontrolled hypertension in patients with increased cardiovascular risk, estimated to be over 7.7 million patients in the U.S. [5][10] - The strategic collaboration between Orchestra BioMed and Medtronic aims to develop AVIM therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients, a population of over 750,000 patients annually [5][10] Group 3: Research and Development - The BACKBEAT global pivotal study is currently evaluating the safety and efficacy of AVIM therapy in patients with systolic blood pressure above target despite anti-hypertensive medication [10] - The MODERATO II study showed that patients treated with AVIM therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure and 12.3 mmHg in office systolic blood pressure at six months compared to control patients [10] - AVIM therapy is compatible with standard dual-chamber pacemakers and aims to substantially and persistently lower blood pressure [10]

Group 1 - The Board of Trustees of Ellsworth Growth and Income Fund Ltd. has increased the quarterly distribution to $0.19 per share, a 20% increase from the previous $0.16 per share [1] - The new distribution will commence in December 2025, raising the annualized distribution rate from $0.64 to $0.76 per share [1] - The increase in distribution reflects the Fund's strong NAV total return of 18% year to date [1] Group 2 - Ellsworth Growth and Income Fund Ltd. is a diversified, closed-end management investment company with total net assets of $199 million [2] - The Fund primarily invests in convertible securities and common stock, aiming to provide income and potential capital appreciation [2] - Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc., manages the Fund [2]

RYE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- The Board of Trustees of GAMCO Natural Resources, Gold & Income Trust (NYSE: GNT) (the “Fund”) authorized a 25% increase in the monthly cash distribution to $0.05 per share from $0.04 per share, beginning in October 2025. The increase reflects the strength of the Fund’s NAV total return of 28% year to date. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the F ...

Group 1 - Curanex Pharmaceuticals Inc. has priced its initial public offering (IPO) of 3,750,000 shares at $4.00 per share, aiming for gross proceeds of $15 million [1] - The IPO is expected to close on August 27, 2025, and shares will begin trading on the Nasdaq Capital Market under the ticker symbol "CURX" [1] - Underwriters have an option to purchase an additional 562,500 shares within 45 days of the offering's close [1] Group 2 - Proceeds from the offering will be used for the development of the lead product candidate, Phyto-N, for ulcerative colitis, including FDA-required studies and IND application preparation [2] - Curanex Pharmaceuticals is focused on developing botanical drugs for inflammatory diseases, with Phyto-N being a botanical extract with proven anti-inflammatory properties [7][8] - Phyto-N has been validated in animal models for six inflammatory diseases, with the primary indication being moderate to severe ulcerative colitis [8] Group 3 - Dominari Securities LLC is the lead underwriter for the offering, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters [3] - A registration statement for the offering was filed with the SEC and declared effective on August 12, 2025 [4] - The final prospectus related to the offering will be available on the SEC's website [4][5]